NCT06359795 Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
| NCT ID | NCT06359795 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Thyroid Eye Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-12-15 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-12-15 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Patients diagnosed with TED; 3. Complete understanding and voluntary participation in this study, with the signing of an informed consent form. Exclusion Criteria: 1. Severe liver or kidney dysfunction; 2. Inability to maintain a supine position for 5 minutes to cooperate with the examination; 3. Suffering from claustrophobia or other psychiatric disorders; 4. Patients planning pregnancy or in the prenatal or lactation period; 5. Other conditions deemed unsuitable for participation in the trial by the investigator.
Contact & Investigator
Hui Li, Dr.
PRINCIPAL INVESTIGATOR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT06359795 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Thyroid Eye Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06359795 currently recruiting?
Yes, NCT06359795 is actively recruiting participants. Contact the research team at huilee1990@163.com for enrollment information.
Where is the NCT06359795 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06359795 clinical trial?
NCT06359795 is sponsored by Peking University Third Hospital. The principal investigator is Hui Li, Dr. at Peking University Third Hospital. The trial plans to enroll 50 participants.